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Abstract
Introduction: Delayed Graft Function (DGF) is a 
common complication of renal transplants and the 
long-term relation between DGF and survival of patients 
and grafts is not well established.
Methods: This is a historical cohort study of transplanted 
patients in Taleghani Hospital of Shahid Beheshti 
University in Iran between 1994 and 2010. Patients who 
required dialysis during the first week after transplantation 
were considered to have DGF. The patients’ conditions 
were updated to determine existing graft function, graft 
loss or patients’ death at one year and five years post 
transplantation in relation to the presence or absence of 
DGF. 
Results: DGF complicated 67/385 transplants (17.4%). 
Causes included acute tubular necrosis (58.2%), 
accelerated rejection (29.9%), transplant renal artery 
thrombosis (9%) and renal vein thrombosis (3%). 
More kidneys in the DGF group were procured from 
cadaveric donors (6% versus 0.9%, P = 0.02). At hospital 
discharge, patients with DGF had significantly higher 
mean creatinine level (4.4±2.8 versus 2.0±1.7; P=0.001) 
compared to other patients. They also had more early acute 
rejection episodes and more late acute rejection episodes 
(34.3% versus 2% and 16.4% versus 3%, respectively; 
P = 0.0001) compared to other patients. The proportion 
of functioning grafts was significantly lower in the DGF 
group at 1-year (53.7% versus 95.3%, P = 0.0001) and 
5-years (22.4% versus 61.6%, P = 0.001) compared to 
patients without DGF.
Conclusion: The DGF group had a significantly higher 
acute rejection rate and an increased risk of graft loss at 
one and five years.
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Introduction
Delayed Graft Function (DGF) is a well-known 
complication that can affect the kidney allograft in the 
immediate post-transplant period. It may be considered 
a form of acute kidney injury caused by ischemia 
reperfusion injury and/or immunological factors [1, 2] 
that may or may not require dialysis.
Risk factors for DGF in the recipient include male gender, 
black race, longer dialysis duration, high panel-reactive 
antibody (PRA) titer, CMV status, number of grafts 
received and greater degree of HLA mismatching. Donor 
related risk factors include use of cadaveric donors, older 
donor age and longer cold ischemia time [3-5]. Most 
of these variables affect the graft through ischemia-
reperfusion injury and immunologic mechanisms. High 
dosage of calcineurin inhibitors (CNIs) could also 
prolong or worsen DGF [6].
DGF is a clinical diagnosis based on clinical, radiological, 
and sometimes histological findings. It increases 
morbidity by prolonging hospitalization and adds extra 
cost. It may also lead to premature graft failure. Some 
studies have indicated an association between DGF 
and reduced graft survival rates, while others have not 
found such a relation [7]. The frequency of DGF varies 
from 4-10% in living donor transplants and 5-50 % in 
kidneys from cadavers [2-4]. Recent data from US Renal 
Database System (USRDS) show a 22% incidence rate of 
DGF in cadaveric allografts [8].
The objective of this study was to assess the frequency 
of DGF among 385 adult kidney transplant recipients in 
our center. In addition, the effect of DGF on patients and 
grafts survival rates was evaluated. 
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Methods
The aim of this retrospective study was to evaluate the 
effect of DGF on survival rates of grafts and patients 
after adult kidney transplantation. For this purpose, 
we reviewed the records of all patients who received 
kidney transplantation at the renal transplantation ward 
of Taleghani Hospital of Shahid Beheshti University in 
Iran between1994 and 2010. Collected data included age 
and gender of donors and recipients, type of transplant 
donor (cadaver, living related, living unrelated), number 
of previous transplants, CMV status of donors and 
recipients, duration of dialysis and results of PRA testing. 
Patients who required dialysis during the first week after 
transplantation were considered to have DGF. Allograft 
function was evaluated by measuring serum creatinine, 
urea, electrolytes and daily urine output. Rejection 
episodes were diagnosed clinically after performing 
color Doppler ultrasonography and renal DTPA isotope 
scan. The patients’ conditions were regularly updated to 
determine existing graft function, graft loss or patients’ 
death. 
Statistical analysis was performed using SPSS (version 
16) for windows. Survival rates for patients and grafts with 
and without DGF were calculated by the Kaplan-Meier 
method. Survival rates were compared by the Log-Rank 
test. Means and medians of quantitative variables were 
compared using student T-test and Mann-Whitney test 
respectively. Categorical variables were compared using 
the Chi-square test. All P-values were two-tailed and a 
P-value <0.05 was considered significant.
Results
The study included 385 renal transplant recipients, 228 
of whom were males and 157 were females. Their mean 
age was 35±14 years. The mean duration of dialysis was 
17±18 months (range 0-96 months). PRA was positive 
in one patient (0.3%). The source of transplanted kidney 
was a living related donor in 15% (58 patients), living 
unrelated donor in 83% (320 patients) and cadaveric in 
2% (7 patients). This was the first transplant in 96.1% 
of cases (370 patients), the second transplant in 3.7% 
(14 patients) and the third transplant in 0.3% (one 
patient). From 385 donors, 313 were males and 72 were 
females. The donors’ mean age was 29 years. Only one 
donor and one recipient were positive for CMV. The 
immunosuppressive regimen included cyclosporine and 
prednisolone plus either azathioprine or mycophenolate 
mofetil. Transplantation was performed by one surgical 
team.
DGF complicated 67/385 transplants (17.4%). Causes of 
DGF included acute tubular necrosis (58.2%), accelerated 
rejection (29.9%), transplant renal artery thrombosis (9%) 
and renal vein thrombosis (3%). Only four patients from 
the DGF group remained dialysis dependent. When we 
compared different baseline characteristics of recipients 
with and without DGF, the only significant difference was 
in the type of kidney donor. More kidneys in the DGF 
group were procured from cadaveric donors (6% versus 
0.9%, P = 0.02) (Table-1). At hospital discharge, patients 
with DGF had significantly higher mean creatinine 
level (4.4±2.8 versus 2.0±1.7; P=0.001). They also had 
more early acute rejection episodes and more late acute 
rejection episodes (34.3% versus 2% and 16.4% versus 
3% respectively; P = 0.0001) compared to other patients. 
Patient status at one and five years is shown (Table-2). 
Patients with DGF had significantly worse patient and 
graft survival rates at one and five years compared to 
other patients (Figures 1-2).  
Discussion
Transplantation is the preferred treatment option for 
most patients with end stage renal disease (ESRD). It 
improves the patients’ quality of life to a greater extent 
than hemodialysis and peritoneal dialysis [9]. Today, graft 
survival has increased with better donor selection and use 
of newer immunosuppressive agents. Patients with poor 
graft function in the immediate post-transplant period 
may require dialysis. The criteria for dialyzing patients 
in the immediate post-transplant period vary from center 
to center. However, using dialysis in the immediate post-
transplant period as the sole criterion for the diagnosis 
of DGF would exclude patients with significant residual 
native kidney function [10].
There are many causes for DGF, such as antibody-
mediated rejection, ischemic acute tubular necrosis 
(ATN), infarction, endothelial damage, acute calcineurin 
inhibitor toxicity, thrombotic microangiopathy, drug-
induced interstitial nephritis and fulminant disease 
recurrence. In this study, DGF occurred in 17.4% of 385 
recipients and ATN was the commonest cause (58.2%). 
This figure is higher than what was reported by Mihatsch 
et al, who stated that approximately 30% of DGF in their 
patients was due to ATN or ischemic injury [11]. Several 
animal studies have shown that DGF due to ATN could 
reduce graft survival due to nephron mass reduction [12]. 
Alloimmune responses that are known to be intensified 
during DGF can also contribute either to acute rejection 
or to accelerated interstitial nephritis and tubular atrophy, 
hence reducing graft survival [1]. On the other hand, if 
DGF is rapidly and completely reversed, there should not 
be any adverse effect on long-term graft survival [13]. 
Therefore, early diagnosis of DGF within the first few 
hours after surgery is crucial. Some techniques utilizing 
urine or serum biomarkers are able to identify DGF early 
[14-18]. However, these highly sensitive tests are rarely 
available at hospital wards. Currently, there is no effective 
treatment for DGF resulting from ATN. Agents effective 
for treatment of DGF in animal experiments have been 
disappointing in clinical setting [19]. 
DGF predisposes the graft to both acute and chronic 
rejection [7]. Sri et al estimated that DGF is associated 
with a 38% increased risk of acute rejection in the first 
year [20]. In the present study we showed that DGF was 
associated with a higher risk of acute rejection in the first 
year. Several studies have shown that patients with DGF 
are at increased risk for graft loss at one, three, and five 
years compared to patients without DGF [7, 21-23], but 
Variables DGF No DGF P value
Recipients gender(male/female) 41/26 187/131 NS
Recipients age (mean ±SD) 38.31±14 33.74±13.66 NS
Duration of dialysis (mean ±SD) 29.29±25.56 15.26±16.57 NS
PRA status (+/-) 0/67 1/317 NS
Number of transplants (first/second/third) 63/4/0 307/10/1 NS
Source of transplanted organ
Living related 10 (14.9%) 48 (15.1%) 0.017              
Living unrelated 53 (79.1%) 267 (83.9%)
Cadaveric 4 (6.0%) 3 (0.9%)
Donor gender(male/female) 56/11 257/61 NS
Donor age (mean ±SD) 29.20±6.65 28.49±6.56 NS
Table1:  Comparison of different variables between patients with and without delayed graft function
DGF: Delayed Graft Function; PRA: Panel Reactivity Antibody
Table2: Recipient status at one and five years follow-up
Total DGF No DGF P value
Status at 1-year
     Functioning graft 339 (88.1%) 36(53.7%) 303(95.3%) 0.0001
     Graft loss 33 (8.6%) 26(38.8%) 7(2.2%)
     Death 10 (2.6%) 5(7.5%) 5(1.5%)
     Inconclusive data 3 (0.8%) 0(0%) 3(0.8%)
Status at 5-year
     Functioning graft 211 (54.8%) 15(22.4%) 196(61.6%) 0.001
     Graft loss 60 (15.6%) 33(49.5%) 27(8.5%)
     Death 19 (4.9%) 10(14.9%) 9(2.8%)
     Inconclusive data 95 (24.7% 9(13.4%) 86(27%)
DGF: Delayed Graft Function
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not with mortality [7, 20]. Nicholson et al found that 
DGF was a significantly more powerful predictive factor 
for poor graft survival (P = 0.001) than acute rejection 
occurring in the first 90 days after transplant [24]. 
Conclusion
In the current study, DGF occurred in 17.4% of 385 
kidney transplant recipients and ATN was the commonest 
etiology. Patients with DGF had a significantly higher 
acute rejection rates and significantly worse graft and 
patient survival.
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